Oct 30 (Reuters) – The European Medicines Agency has started a review of depression and anxiety medicine Deanxit, made by Danish drugmaker H Lundbeck, after reports of “serious neurological and psychiatric side effects”.
Here are some details:
• EMA’s Pharmacovigilance Risk Assessment Committee said on Friday the reports relate to cases involving movement disorders, and memory and thinking problems
• The PRAC added that in some cases, symptoms persisted after stopping the treatment
• H Lundbeck did not immediately respond to a request for comment
(Reporting by Vera Dvorakova and Bhanvi Satija; Editing by Mrigank Dhaniwala)
Comments